ABBV240628P130000
- 0.01
- 0.000.00%
AbbVie Newsroom
Watching Cerevel Therapeutics; Traders Circulating M&A Blog Comments Saying A Recommendation Memo From The Staff At The FTC To "Challenge" The CERE/ABBV Merger Is Being Considered
Watching Cerevel Therapeutics; Traders Circulating M&A Blog Comments Saying A Recommendation Memo From The Staff At The FTC To "Challenge" The CERE/ABBV Merger Is Being Considered
AbbVie Hits 4-week Low
Company News for Jul 3, 2024
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
7 analysts have expressed a variety of opinions on AbbVie (NYSE:ABBV) over the past quarter, offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessments, the table
Piper Sandler Maintains Overweight on AbbVie, Maintains $190 Price Target
Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and maintains $190 price target.
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 14.55% Piper Sandler $190 → $190 Maintains Overweight 06/20/2024 20.58% Cantor Fitzgerald $200
Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.
Shares of Pharmaceutical Stocks Are Trading Lower After Biden Called on Novo Nordisk to Cut Ozempic and Wegovy Prices.
With 72% Ownership, AbbVie Inc. (NYSE:ABBV) Boasts of Strong Institutional Backing
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $190
Piper Sandler analyst Christopher Raymond maintains $AbbVie(ABBV.US)$ with a buy rating, and maintains the target price at $190.According to TipRanks data, the analyst has a success rate of 51.1% and
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill., July 2, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2024 financial results on Thursday, July 25, 2024, before the market opens. AbbVie will host a li
Morgan Stanley Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $191
Morgan Stanley analyst Terence Flynn maintains $AbbVie(ABBV.US)$ with a buy rating, and maintains the target price at $191.According to TipRanks data, the analyst has a success rate of 65.1% and a tot
Buy Rating Affirmed for AbbVie on Strong Aesthetics Market Position and Positive Sales Outlook
AbbVie Names Robert A. Michael CEO; Richard A. Gonzalez To Become Executive Chairman
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswi
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
Express News | Robert a. Michael Assumes Role as Abbvie Chief Executive Officer
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael Joins AbbVie Board of DirectorsNORTH CHICAGO, Ill., July 1, 2024 /PRNewswi
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
AbbVie, Genmab Blood Cancer Therapy Endorsed in EU
AbbVie (ABBV.US) has reached a $250 million acquisition agreement and obtained a potential first-in-class therapy.
Recently, AbbVie (ABBV.US) announced the acquisition of Celsius Therapeutics for a total consideration of USD 250 million.